Ibuprofen Brand Ranking

Shenwei Pharmaceutical Group Co., Ltd.

Shenwei Pharmaceutical Group is a large comprehensive enterprise group with the new Chinese medicine industry as its main business, and is listed on the main board of the Hong Kong Stock Exchange. Its main business covers Chinese medicinal materials cultivation, Chinese medicine preparations, Chinese medicine formula granules, Chinese herbal medicines, health products, and biopharmaceuticals. The upstream, midstream and downstream industrial chains have achieved full coverage of the new Chinese medicine industry from the field to the terminal, and are one of the large pharmaceutical enterprise groups with a relatively complete layout in the big health industry. Shenwei Pharmaceutical has formed special products such as modern Chinese medicine injections, modern Chinese medicine soft capsules, modern Chinese medicine granules, and Chinese medicine formula granules for the rapid growth of drugs for middle-aged and elderly people, children's medicine, antiviral drugs, and orthopedic drugs. Looking to the future, Shenwei Pharmaceutical will continue to deepen its development in the new Chinese medicine industry, continuously strengthen its professional academic marketing capabilities and precise brand management capabilities, and be the maker of modern Chinese medicine standards, the leader of modern Chinese medicine technology, and the guarantee of modern Chinese medicine quality. A demonstration of modern Chinese medicine innovation, leading modern Chinese medicine, promoting the health industry, and creating a century-old magical power.

Jilin Wutai Gankang Pharmaceutical Co., Ltd.

As the first brand of Wutai Group, "Guankang" entered the market in 1996 and has been sold for more than 20 years. Its sales volume has been at the forefront of domestic cold medicine products for many years. "Gankang" brand growth process: 1995: A decision that was of historic significance to Wutai Group - the acquisition of Jiangcheng Pharmaceutical Factory, Wutai Group entered the field of pharmaceutical industrialization. In the same year, the antiviral cold drug "Guankang" was developed and launched. "Gankang" has achieved great success with its accurate market positioning and marketing strategy. After it was put on the market, its brand value continued to rise and its reputation gradually expanded. 1998: In the Jilin Provincial Medical Market Census of Jilin Provincial Social Investigation Firm, "Guankang" was recognized as a high-quality representative product for cold resistance. 2015: Since 2015, the company has made drastic packaging reform and innovation. In 2016: The company developed a "pull-pull-type new packaging" and owned six patents. 2020: Gankang animation image is released for the first time.

Harbin Pharmaceutical Group Co., Ltd.

Harbin Pharmaceutical Group Co., Ltd. ( hereinafter referred to as "Habin Pharmaceutical Co., Ltd." ) is a large enterprise group integrating pharmaceutical manufacturing, trade and scientific research. In June 1993, the company was listed on the Shanghai Stock Exchange (stock code "600664"). The company covers three core business segments of industrial manufacturing, commerce and GNC. It has 10 industrial enterprises including Harbin Pharmaceutical Sanjing, Harbin Pharmaceutical General Factory, Harbin Pharmaceutical Six Factory, and Harbin Pharmaceutical Shiyitang. Harbin Pharmaceutical Renmin Tongtai (listed company ) and Harbin Pharmaceutical Marketing two commercial distribution companies, and also has a pharmaceutical research institute with strong scientific research capabilities, focusing on innovative research and development in high-tech fields such as central nervous system, anti-tumor, cardiovascular and cerebrovascular drugs. Hayao Co., Ltd. has 1,816 drug approvals and 74 health food approvals. The leading products include calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, prostadil injection, and pediatric aminophen yellow. Namin granules, Rasidipin tablets, ceftiam hydrochloride for injection, ibuprofen granules, Xingai Zhonggai brand high calcium tablets, etc. The company owns five trademarks: "Haya Medicine", "Three Essences", "Guizhong Gai", "Hutong" and "Shiyitang", with a brand value of more than 20 billion yuan. Integrity, professionalism, openness and inclusiveness, collaboration and responsibility, innovation and efficiency are the core values ​​of corporate development. Harbin Pharmaceutical Co., Ltd. is an enterprise with relatively innovative capabilities and pioneering spirit. In the future, the company will coordinate the talent chain, industrial chain and capital chain, comprehensively build an open innovation ecosystem, constantly explore high-quality development paths, and continue to make efforts in many fields such as products, technology, R&D, intelligent manufacturing, business models, and management mechanisms. Breakthrough and transformation make Harbin Pharmaceutical a benchmark for Chinese national pharmaceutical companies that consumers, customers, employees and society are proud of.

Roosin Medical Co.,Ltd

ROOSIN medical is a worldwide medical solutions company. Founded in 1996, we keep focusing on the development of world-class wound dressing products that offer high quality solutions for our caregivers and patients. ROOSIN medical aims to strengthen our position as a reliable company through innovation and continuous improvement. And recognized as a provider of specialty patient-care products within the medical device industry, we offer global solutions to improve the quality of life. Our well-known products such as Xeroform Petrolatum Gauze Dressing, Calcium Alginate Dressing, silver alginate dressing, Burn Dressing, hydrocolloid wound dressing and chest seal.

Renfu Pharmaceutical Group Co., Ltd.

Renfu Pharmaceutical Group Co., Ltd. was established in 1993 and listed on the Shanghai Stock Exchange in 1997. It is the leading pharmaceutical industry enterprise in Hubei Province's National Enterprise Technology Center, a national technological innovation demonstration enterprise, and a leading enterprise in the internationalization of Chinese pharmaceutical enterprise preparations. Domestic narcotic drugs, steroid hormone drugs, Uyghur ethnic medicines have established a leading position in many sub-sectors. The company is mainly based on the pharmaceutical industry and supplemented by the pharmaceutical business, and is steadily promoting internationalization. The pharmaceutical industry has achieved full dosage form production capacity of pharmaceutical intermediates-raw materials-pharmaceutical excipients-pharmaceutical preparations in the entire industry chain; pharmaceutical business adheres to the positioning of "comprehensive medical service supplier", lays out commercial networks, and achieves full regional coverage; internationalization has formed The full value chain capability of pharmaceuticals for global R&D, registration, production and sales has been exported to more than 80 products in more than 70 countries and regions around the world. Based on innovative drugs, innovative preparations and high-end generic drugs with high clinical value, the company aims at cutting-edge fields and creates a first-class innovative R&D industrialization platform. R&D centers have been set up in Wuhan, Yichang, China, New Jersey, St. Louis and other places in the United States. The group has more than 500 projects under development, including more than 30 new drugs in Class I, and has obtained 778 authorized patents. Renfu Pharmaceutical firmly adheres to the development strategy of "being a leader in the pharmaceutical market segment". Through the three strategic paths of "focusing, innovation, and internationalization", it gradually realizes the leap from international follow-up to leading, and creates global competitiveness. a world-class pharmaceutical company.

Zhuhai United Laboratories Co., Ltd.

Federal Pharmaceutical was founded in 1990 and listed in Hong Kong in 2007. The stock code is 3933.HK, mainly engaged in the research and development, production and sales of drugs. After more than 30 years of development, Federal Pharmaceutical has formed a comprehensive pharmaceutical group with four major business segments: preparations, raw materials, biology, and animal welfare, and nine production and R&D entities. Its sales network covers the world and currently has more than 16,000 employees. Since its establishment, Federal Pharmaceuticals has been committed to providing high-quality products and services to the society and promoting high-quality development of the pharmaceutical industry. It is one of the leading comprehensive pharmaceutical companies in China. Zhuhai Federal Pharmaceutical Co., Ltd. was registered and established in 1993. The factory was completed and put into production in 1998. Currently, production bases have been established in Sanzao Town and Nanshui Town, Jinwan District, Zhuhai City, covering a total area of ​​450,000 square meters and employees are about 2,700. people. After more than 20 years of development, it has become a high-tech modern comprehensive pharmaceutical enterprise integrating production and R&D. The company's main products include more than 50 varieties of insulin, penicillin, cephalosporin, carat, and penem. Oral semi-synthetic penicillin workshop is currently a production workshop with a large production capacity of similar products in China, with an annual production capacity of more than 5,000 tons. The annual production capacity of the "Golden Feiyan" and "Silver Feiyan" brand products of the cephalosporin series and the carat series are about 1,000 tons. Products sold worldwide. Federal Pharmaceuticals is a company that uses genetically engineered Pichia cerevisia expression technology to produce insulin products, and is also a company that has an insulin prefilled pen assembly line in China. In 2009, the second generation of insulin human insulin (Yusling) was launched. In 2016, the third generation of insulin analog insulin glargine (Yusling) was launched. In 2021, the insulin aspart was launched, and Federal Pharmaceutical became the same. Domestic companies with second and third generation insulin production capabilities. After the project reaches full production, the production capacity will reach 3 tons of raw materials and 300 million preparations, with an annual output value of more than 10 billion yuan. Introducing intelligent manufacturing, Zhuhai Company is an enterprise that adds sterile operation robot intervention system to the sterile raw material industry. It uses robots instead of manual operation in A-level clean areas to ensure the quality of sterile drugs and reduce safety risks. The explored intelligent manufacturing has a profound impact on the quality assurance of sterile pharmaceuticals and the application of industrial intelligence. Taking a diversified development path, Federal Peptide Beauty is a company that has created a polypeptide cosmetic raw material brand for skin care. Its main effects include whitening, firming, anti-wrinkle and anti-aging. In 2017, the use of peptide raw materials into finished cosmetics began, opening a new era of federal peptide beauty skin care. In line with the international level, the quality system insists on international capacity building, and Zhuhai Company always puts quality work first. All series of products such as insulin and antibiotics have passed the domestic GMP compliance test. Amoxicillin and ampicillin raw materials have been subjected to German GMP certification inspections many times. Amoxicillin sodium, potassium clavulanate and other sterile raw materials have obtained the EU CEP certificate, and sterile raw materials such as ampicillin sodium and sulbactam sodium Together, we have successively passed the official joint GMP inspections of EDQM and Spain and other officials. In the future, Federal Pharmaceutical will continue to promote industrial upgrading and innovative development, develop more safe and effective drugs, and make greater contributions to human health.

Hubei V-Medical Products Co.,ltd

Hubei V-Medical products Co., LTD., founded in August 2004, is an joint venture by Beijing Kataijia, France RAFFIN and Israel NISSAN. The company covers an area of 50 acres, with a construction area of more than 30,000 square meters, and has a standard purification workshop of nearly 10,000 square meters, a sterilization center with a sterilization capacity of 110 cubic meters per day, and a fully functional laboratory and testing center, which can complete the work of ethylene oxide residue, positive control, microbiology and asepsis testing. The main products of the company are surgical kits, first-aid kits, dressing kits and other medical combination kits, wound care products such as gauze (non-woven) rolls/swabs/balls/abdominal pads, surgical gowns, isolation gowns, masks (medical/surgical /KN95) and other hygienic personal protective products, as well as various medical bandages. Our products are mainly exported to Europe, America and the Middle East. The company has obtained ISO13485 quality system certification, ISO11135 sterilization certification, ISO14000 and CE product certification, domestic medical device production license. The second class products registered in China include disposable first aid kit, disposable surgery kit, medical mask, medical surgical mask, etc. At the same time, there are more than 10 categories of products registered in FDA.

North China Pharmaceutical Group Corporation

North China Pharmaceutical Group Co., Ltd. (hereinafter referred to as Hua Pharmaceutical Group) is located in Shijiazhuang, the capital of Hebei Province. The predecessor of North China Pharmaceutical Factory was a key construction project during China's "First Five-Year Plan" period. It was started in June 1953 and completed and put into production in June 1958. It has created a history of large-scale antibiotic production in my country, and has been used for the development of human health and the national pharmaceutical industry. It has made important contributions to changing the situation of shortage of doctors and drugs in my country. In 1992, it was reorganized and established North China Pharmaceutical Co., Ltd., and was listed on the Shanghai Stock Exchange in 1994 (stock name: North China Pharmaceutical 600812). In January 1996, North China Pharmaceutical Factory was officially reorganized into a wholly state-owned company - North China Pharmaceutical Group Co., Ltd. In June 2009, with the approval of the Hebei Provincial Government, Jizhong Energy Group implemented a restructuring of Hua Pharmaceutical Group. Over the years, Huayao Group has adhered to the corporate purpose of "human health first, quality always comes first", continuously innovated, operated steadily, gradually expanded its business scope, maintained excellent development performance, and its main economic and technical indicators have always been at the forefront of the domestic industry. . As of the end of 2018, Huayao Group had a total assets of 20.6 billion yuan, nearly 15,000 employees, and more than 40 subsidiaries (branches) companies, including the National Engineering Research Center for Microbial Drugs, the National Key Laboratory for Antibody Drug Development, Antibiotic Enzyme Catalysis and Crystallization technology, the three innovative platforms of the National and Local Joint Engineering Laboratory, mainly include nearly a thousand product specifications in the fields of chemical pharmaceuticals, modern biotechnology drugs, vitamins and nutritional health products, modern Chinese medicine, biological agricultural and veterinary medicine, etc. The treatment field covers anti-infection categories , cardiovascular, kidney disease, anti-tumor and immunomodulation, etc. The process routes and production layout of the main production units are all designed and implemented in accordance with the current European and American versions and the new Chinese version of GMP standards, and have a modern pharmaceutical production platform with international advanced standards.

Johnson & Johnson (China) Investment Co., Ltd.

In 1995, Johnson & Johnson, the United States established a pharmaceutical company specializing in the production of self-health drugs in Shanghai - Shanghai Johnson & Johnson Pharmaceutical Co., Ltd. (hereinafter referred to as "Shanghai Johnson & Johnson Pharmaceutical"). Through continuous innovation, Shanghai Johnson & Johnson Pharmaceutical provides high-quality products to patients and consumers in the fields of colds, coughs, fever, pain, allergies, etc. The company's products have been recognized by professional medical staff and pharmacists. A series of products that have been successfully launched so far have been widely known and recognized by patients and consumers, including: Tylenol (Phenol Amemin Tablets/Phenol Amemin Suspension), Tylenol Norin (acetaminophen sustained release tablets), Tylenolin (acetaminophen suspension drops/acetaminophen oral suspension), Merrillin (ibuprofen suspension/ibuprofen suspension Drops), Aishu (Yu Pseudo-Masume oral solution/dextromethorphan guaifene ether syrup) and Aishu (Psychological Masumethorphan drops), Helifuting (levocasubastin hydrochloride nasal spray), etc. . The company has always adhered to a high level of professional ethics and its commitment to improving the quality of life of the public. Johnson & Johnson Pharmaceutical insists on taking social contributions as its mission, actively participates in social welfare undertakings, and continues to donate to disaster areas, poor areas, etc. through various social welfare groups, so as to transform the belief in corporate social responsibility into practical actions.

Tian Da Pharmaceutical Co., Ltd.

Tianda Pharmaceutical Co., Ltd. (hereinafter referred to as Tianda Pharmaceutical, a listed company on the Hong Kong Stock Exchange, stock code 0455) is based on the development of the traditional Chinese medicine industry, develops innovative drugs and medical technology, develops high-quality medical and health care services, and is committed to becoming a pharmaceutical product. Pharmaceutical companies with market competitiveness and core value chains in the fields of research and development, medical technology, traditional Chinese medicine diagnosis and treatment, and health management. Tianda Pharmaceutical has built a full traditional Chinese medicine industry chain from the three aspects of traditional Chinese medicine, traditional Chinese medicine and traditional Chinese medicine intelligence, established the "Tianda Standard" to control the quality of traditional Chinese medicine materials, and established a new Chinese medicine clinic - Tianda Pavilion. As a platform for traditional Chinese medicine diagnosis and treatment and health management, Tiandaguan adheres to the traditional Chinese medicine concept of "preventing diseases before they are sick", adheres to the treatment principle of "stop diseases when they are sick, and people-oriented", is based in the Guangdong-Hong Kong-Macao Greater Bay Area, and is located in the whole country and globally, striving to develop into traditional Chinese medicine The first brand of the museum; and make full use of Internet information technology, big data, artificial intelligence and other innovative technologies to build a "Cloud Heaven Hall" to realize the integration of online and offline traditional Chinese medicine services, remote diagnosis and treatment and expert consultation, and provide the public with High-quality, convenient and comprehensive traditional Chinese medicine health services have become the leader in promoting the inheritance, innovation and development of traditional Chinese medicine. Tianda Pharmaceutical focuses on the development of global pharmaceutical and health technology and the latest achievements, continuously increases R&D investment, strengthens innovation, accelerates technological progress, optimizes product structure and improves service levels, and forms a sustainable competitive advantage. The company's products include traditional Chinese medicine, chemical drugs, biological products, health products and medical devices, etc., covering the fields of cardiovascular, pediatrics, colds and respiratory, anti-infection, anti-addiction, anti-tumor and other therapeutic drugs, as well as "Hegu" , "Tokang" brand series of health products, etc. Tianda Pharmaceutical relies on the Chinese market, strives to expand the international market and build a global marketing network. The company has set up marketing centers in Shenzhen and Zhuhai, China, responsible for sales and brand building in the Chinese market. Through distributors and terminal retailers in various provinces, cities and regions, products are sold well all over the country; established wholly-owned subsidiaries in Hong Kong and Australia, and gradually Establish branches in the United States and Europe, responsible for sales and brand building in Hong Kong, Macao, Australia and international markets. Tianda Pharmaceutical is guided by market demand, expands medical and health care services, and works with high-quality domestic and foreign partners to integrate advanced treatment and health care technologies to build a global health examination, health management, health consultation and chronic disease prevention and control system to meet the growing , different levels of medical and health care needs to better protect the health and well-being of the general public. Your health is a big deal! This is the vision and slogan of Tianda Pharmaceutical, expressing Tianda Pharmaceutical's desire and pursuit to continuously contribute health and care. Taking this as a driving force, Tianda Pharmaceutical strives to develop into a leading pharmaceutical company based in China and radiates to the world.

Xiangyu Pharmaceutical Co., Ltd.

Xiangyu Group was founded in 1986 and has gone through five stages and four transformations. It has now developed into a modern pharmaceutical enterprise. The main industries of the enterprise are among the top 100 in the country. Xiangyu Pharmaceutical mainly produces gynecological drugs represented by compound red blood replenishing oral liquid, pediatric drugs represented by Xiangma Hanpan patch, psychotropic drugs represented by Mianselin hydrochloride, and Yishen Granules. 11 types of preparations such as tonic medicine, with more than 200 varieties and more than 300 product specifications, and are committed to creating a "first-line brand of Chinese maternal and child medicine". The company invests no less than 10% of its sales revenue each year in scientific and technological research and development, and has successively established scientific research platforms such as the National Enterprise Technology Center, Academician Workstation, Postdoctoral Research Workstation, and New Gynecological Drug Preparation Engineering Research Center.

Beijing Hanmi Pharmaceutical Co., Ltd.

Beijing Hanmei Pharmaceutical Co., Ltd. (hereinafter referred to as Beijing Hanmei) was established in March 1996 and is located in the beautiful environment of Beijing Shunyi Airport Development Zone, covering an area of ​​13,600 square meters. In addition to its headquarters, Beijing Hanmei also has a research center, a GMP factory and a sales team all over the country. In 2008, it established an international "Business Center" (Business Center) with an international level, integrating "R&D, Production, and Sales". Located in one. Among them, the GMP factory was carefully designed and built strictly in accordance with the GMP standards. It passed the GMP certification of the State Administration of Drug Administration for the first time in December 2001 and officially put into production and use, and passed the new version of the GMP certification at the end of 2015. The research center has an area of ​​nearly 4,000 square meters, including biological laboratories, chemical synthesis laboratories and pharmacological toxicology laboratories. It is equipped with a variety of international drug research equipment, and is equipped with advanced foreign research and development centers, Korean and American pharmaceutical headquarters, Korean and American fine chemical engineering The factory and formula R&D center work closely together to form a global R&D network. The sales team covers all provinces, autonomous regions, municipalities directly under the central government and hundreds of cities and counties in China. The company's product business involves pediatric products, gastroenterology products, orthopedic products, anti-infective drugs and other fields. 98% of the products are produced in China. The main products include Mommy Ai, Yi Tanjing, Yi Anping, Mei Chang'an, Li Dong, and Vinegar. More than a dozen varieties such as clofenac and Ruimai. Among them, Mommy Ai and Yi Tanjing have become basic regular medicines for children in China and are very popular among doctors and children's parents. In 2019, Mommy Love launched a series of probiotic infant and toddler cleaning products to help Chinese babies have healthy skin and to take care of the healthy growth of infants and toddlers. 2021 marks the 25th anniversary of the establishment of Beijing Hanmei Pharmaceutical Co., Ltd. In July of the same year, the company invested 300 million yuan to build a new intelligent automation warehouse with an area of ​​about 1,800 square meters and a pharmaceutical workshop known as "having a large domestic oral liquid production line". The completion and opening marks a new step in the industrialization development of Beijing, South Korea and the United States.

Topwin(Hubei) Medical Products Manufacturer

Company Introduction Topwin Medical Products is a professional manufacturer of disposable medical gauze, non-woven and bandage products with almost 40 years history. We have three factories in Hubei Province now with a total area of 100000 m2 and 500 employees. We have established a standard quality management system and have ISO 13485 certificate. Who We Are: Topwin was established in 1999 and produces Medical Dressings, Protective consumables for export. Our major items include Laparotomy Sponges, Gauze Swabs, Non-woven Sponges, Elastic Bandages, Tubular Stockinette, Face masks and all kinds of Non-woven disposables. Our facilities locate in Central China where cotton and non- woven supplies is profound with quality. Our office locates in Wuhan who enjoys convenient transportations by Air, by railway, by highway and by water channel. With nearly thirty year experience, Topwin continues to be one of leading players in Medical Disposables industry. We are ready to offer you medical dressing and medical instruments of high quality with competitive price as well as best service.

Teiyi Pharmaceutical Group Co., Ltd.

Teyi Pharmaceutical Group Co., Ltd. (hereinafter referred to as Teyi Pharmaceutical) is a pharmaceutical listed company (stock code 002728) integrating pharmaceutical research and development, pharmaceutical industry, and pharmaceutical commerce. Its subordinate enterprises are distributed in Guangdong, Hainan, Anhui and other regions. Teyi Pharmaceutical and its wholly-owned subsidiary Hainan Haili Pharmaceutical Co., Ltd. and Taishan Xinning Pharmaceutical Co., Ltd. are both national high-tech enterprises. Teyi Pharmaceutical has been successively rated as "Outstanding Contributor Enterprise in the Pharmaceutical Industry in Guangdong Province", "Netherlands Science and Technology Enterprise in Guangdong Province", "Netherlands Innovation Industrialization Demonstration Base", "Netherlands Innovation Enterprise in Guangdong Province", and "Abide by Contracts and Harmony Credit enterprises", "A-level taxpayer", "AA-level credit-grade customer", etc.; Hainan Haili Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Teyi Pharmaceutical, has been successively rated as "National Intellectual Property Advantage Enterprise in 2018" and "Hainan Leading enterprises in the industrial industry (Chinese patent medicine manufacturing industry)", "national quality, service, and reputation AAA enterprises" and "A-level taxpayers", etc. Teyi Pharmaceutical industry includes Taishan pharmaceutical production base (formerly Guangdong Taicheng Pharmaceutical), Haikou pharmaceutical production base (Hainan Haili Pharmaceutical Co., Ltd.), raw material pharmaceutical production base (Taishan Xinning Pharmaceutical Co., Ltd.) and chemical product production base (Taishan Chemical Factory Co., Ltd.). Teyi Pharmaceutical Group's products include Chinese patent medicines, chemical preparations, chemical raw materials and chemical products. Among them, the "Special One" brand series covers cough and phlegm relief, kidney nourishment, anti-infection, cardiovascular and cerebrovascular and digestive system medications, among which the main preparation products include cough and anti-inflammatory tablets, Pudilan anti-inflammatory tablets, Xuesaitong dispersed tablets, Yixinshu Granules, Ginkgo Leaf Dispersion Tablets, Jinkui Shen Qi Tablets, Magnesium Aluminum Carbonate Chewable Tablets, Erythromycin Enteric Coated Tablets, Erythromycin Tablets, Rorythromycin Capsules, Amoxicillin Capsules, Omeprazole Enteric-coated capsules, etc.; the main chemical raw materials and chemical products include magnesium aluminum carbonate, sodium phenytoin, ferrous sulfate, glacial acetic acid, calcium chloride, sodium chloride, bismuth series, citric acid series, zinc sulfate, etc. Teyi Pharmaceutical's core product is cough-relieving tablets. Its secret recipe was included in the Lingnan Traditional Chinese Medicine Cultural Heritage Protection List (the first batch) in 2009 and was recognized as a key new product in Guangdong Province in 2012; a wholly-owned subsidiary Taishan Xinning Pharmaceutical The key products produced by the Co., Ltd. are magnesium aluminum carbonate, sodium phenytoin, glacial acetic acid, calcium chloride and other raw materials, and are ranked among the top in the national market share. Sodium chloride for injection and bismuth nitrate for basic use have been awarded the "National Medical Administration's high-quality product". In 2018, Teyi Pharmaceutical added pills and eye drops through asset acquisition. The main varieties of pills include Xuedu Pills, Xiaozhu Pills, Tongmai Zhanzhi Pills, Ruyi Dingpan Pills, Wulin Pills, Anti-Tube Pills, Menstrual Freckle Pills, etc. The main products of eye drops include compound dextran 70 eye drops wait. At the same time, the original product combination has also been enriched, such as the respiratory system, including Pudilan anti-inflammatory tablets, Hanhuangling Granules, Xiqingguo Granules, etc., the digestive system, Fengliao Intestine Weakang Tablets, etc., and Zhuangyao Jianshen Pills in Buyi. , Bushen Banlong Capsules, etc. have improved the segmentation of the product line for Teyi Pharmaceutical and also provided guarantees for the segmentation and refined promotion of sales channels. Teyi Pharmaceutical Group currently has two nationwide sales and commercial platforms, among which Guangdong Teyi Haili Pharmaceutical Co., Ltd. operates the "Teyi" brand series produced by Teyi Pharmaceutical Industry. Another commercial platform is Hainan Haili Doctor Pharmaceutical Group Co., Ltd., which operates OEM products of the "Haili Doctor" brand and adopts regional agency sales across the country, including Chinese patent medicines and chemical preparations, and is also diversified by Teyi Pharmaceutical. , an important support for the development of professional value-added business direction. In the future, Teyi Pharmaceutical will continue to adhere to the corporate purpose of "focusing on quality, strengthening R&D, and sustainable development", with endogenous growth as the core and external growth as the auxiliary, strengthen resource integration and internal potential tapping, and strive to build excellent brands and maintain the enterprise. and become a competitive pharmaceutical company.

Shandong Xinhua Pharmaceutical Co., Ltd.

Shandong Xinhua Pharmaceutical Co., Ltd. was established in 1943 in Jiaodong Anti-Japanese Base Area. It is an early chemical synthetic pharmaceutical enterprise in New China. It is an important global production and export base for antipyretic analgesics and painkillers. It is an important domestic cardiovascular and anti-infection. Manufacturers of nervous system, steroid hormone drugs, etc. It has four major business segments: chemical raw materials, pharmaceutical preparations, pharmaceutical intermediates, and e-commerce business, 5 industrial parks and 14 subsidiaries. The annual production capacity of chemical raw materials is 50,000 tons, 500,000 tons of pharmaceutical intermediates, 32 billion solid preparations (particles), and 1.5 billion injections. The annual export volume is nearly US$400 million, and it has established long-term strategic cooperative relations with more than 200 well-known multinational companies including Roche, Bayer, and Bailey. Xinhua Pharmaceutical is a listed company in H-share and A-shares. Xinhua Pharmaceutical is a national high-tech enterprise, a key high-tech enterprise of the National Torch Plan, and a backbone enterprise of the National Torch Plan biopharmaceutical industry base. It has a national enterprise technology center, and has academician workstations, postdoctoral workstations, Taishan industrial talent positions, Taishan scholar positions, There are six major talent platforms including the Master's Joint Training Point and Shandong Technician Workstation. In recent years, Xinhua Pharmaceutical has increased its school-enterprise cooperation efforts and established comprehensive strategic cooperative relations with the Chinese Academy of Medical Sciences, Tsinghua University, Shandong University, Shenyang Pharmaceutical University, Qingdao University of Science and Technology, etc. Six centers including the Medicinal Chemistry Research Center and the Drug Preparation Research Center have been built, covering 12 directions including digestive system, pain control, cardiovascular and cerebrovascular system, anti-metabolic system, nervous system, nutritional health, hormones, etc. , increase R&D investment and lay out more than 100 new products. A total of 21 products and 27 specifications have passed consistency evaluation, and have 8 national first-class new drug documents and 21 second-class new drug documents and obtained 266 authorized patents. It is a three-star "Chinese Patent Shandong Star Enterprise". Xinhua Pharmaceutical's quality value of "product quality is related to the life of the enterprise, and drug quality is related to the life of the person" has been thoroughly implemented by all employees and throughout the process. The company focuses on quality investment and has established a quality control system for the entire process from the entry of raw materials into the factory and the production link to the exit of the product. In the 1990s, Xinhua Pharmaceutical won the domestic "Excellent Quality Management Award". 23 products have won high-quality product awards at the provincial and ministerial levels and above, of which 3 products have won the national gold award and 3 products have won the national silver award. At present, all drugs in production in Xinhua Pharmaceutical have passed the national new version of GMP certification, and have obtained 22 US FDA registration documents, 12 EU EDQM documents, and 3 ANDA documents. Xinhua Pharmaceutical Modern Pharmaceutical International Cooperation Center has passed the China NMPA, GMP certifications such as the UK MHRA, the US FDA and the EU, the preparation products produced by the center are qualified to be sold to international markets such as Europe, the US and the UK, and have exported more than 5 billion tablets in total. In recent years, Xinhua Pharmaceutical has launched a batch of new drugs such as: National Class I innovative drugs, new non-hormonal anti-inflammatory and anti-allergic drugs----------------------------------------------------------------------------------- Shutaide (rabeprazole sodium enteric-coated tablets), Jiaheluo (glimediide tablets), the drug for treating cardiovascular and cerebrovascular treatment (aspirin enteric-coated sustained-release tablets), the National Class 3.1 new drug insurance Chang (Jocal calcium tablets), Fuya'an series three high-purity fish oil health products, and unique dosage form nimodipine sustained-release capsules, the main products are included in the national medical insurance catalog. As a state-owned holding enterprise with red gene, Xinhua Pharmaceutical has always adhered to the corporate mission of "protecting health and benefiting society" and actively fulfilled its social responsibilities. Especially in the three years of fighting the epidemic, Xinhua People do not uphold conditions, live up to their mission, and do their best to do their best. Production and supply of drugs. Especially since the adjustment of the epidemic prevention and control policy in December 2022, the national allocation task was successfully completed in just over 20 days, and a total of 800 million pieces of ibuprofen and other heat-relieving towns were supplied to 31 provinces (municipalities directly under the central government, autonomous regions) across the country. Pain drugs (most of the ibuprofen tablets in the Beijing market are supplied by Xinhua Pharmaceuticals) have effectively guaranteed the people's drug needs and truly reflected the responsibility of state-owned enterprises. The Ministry of Industry and Information Technology, Beijing, Tsinghua University, Fujian Province, Nanjing, Dalian, Yangzhou City and other cities have successively sent letters of condolences and thanks to Xinhua Pharmaceutical, giving high recognition and praise for Xinhua Pharmaceutical's full efforts to ensure the supply of key drugs for the epidemic. Over the years, the company has highlighted the connotation of quality, internationalization, science and technology and responsibility, and has created professional characteristics through all-round means, establishing a good image of quality Xinhua, international Xinhua, science and technology Xinhua and responsibility Xinhua. Xinhua Pharmaceuticals was listed in Shandong Province's first batch of "Honorable Shandong Business" five-star brand image list, and won the National Model Labor Relations Harmonious Enterprise, National Green Factory and Green Supply Chain Enterprise, China Quality Integrity Enterprise, Shandong Province All Staff Innovation Enterprise, Shandong The provincial talent work unit, the leading science and technology enterprise in Shandong Province, and the Shandong Province's advanced collective in fighting the new crown pneumonia epidemic are honored.

Zhuhai Runduo Pharmaceutical Co., Ltd.

Zhuhai Rundu Pharmaceutical Co., Ltd. is a modern technology-based pharmaceutical enterprise integrating drug research and development, production and sales. It is located in Jinwan District, Zhuhai City, Guangdong Province and was established in 1999. On January 5, 2018, the company was listed on the Shenzhen Stock Exchange (Securities abbreviation: Rundu Co., Ltd.; Stock code: 002923). The company currently has more than 1,300 formal employees (including wholly-owned subsidiaries). The company's main business is the research, development, production and sales of chemical preparations, chemical raw materials, and pharmaceutical intermediates. The product application scope covers peptic ulcers, hypertension, surgical anesthesia, antipyretic analgesia, anti-infection, diabetes and other products. field. The company has a complete quality management system and has established a drug production and manufacturing center strictly in accordance with the requirements of the national GMP. The existing product production lines (covering raw materials, tablets, capsules, preparation intermediates (micropellets), etc.) have passed the new national GMP version. Certification, some specialty raw material products have passed the official certification of the World Health Organization, the European Union, Japan, etc., and some products have passed the on-site inspection of the US FDA. While the company continues to maintain outstanding development of unique new dosage forms of drugs (micro-pill capsule preparation technology, micro-pill tableting preparation technology, etc.), enteric-coated and slow-release preparation technology, it actively develops the development of original innovative drugs and multiple varieties of drugs. Technology upgrade; gradually promote the vertical integration of raw materials to preparations; carry out diversified R&D models, strengthen cooperation with R&D institutions with complete domestic and foreign technology, develop a series of preparation products, promote the company's international trade, and gradually realize The company's internationalization strategy strives to build a domestic enterprise that produces special products such as micropill preparations, anti-hypertensive sartan drugs, anti-peptic ulcer proton pump inhibitors and other special products.

Shiyao Holdings Group Co., Ltd.

Shiyao Holding Group Co., Ltd. is a national innovative enterprise integrating the research and development, production and sales of innovative drugs. The total existing assets of the entire group are more than 58 billion yuan and have 28,000 employees. Hong Kong listed company (01093.HK) has entered the 100 billion market capitalization club and is a constituent stock of the Hang Seng Index. In 2019, the subsidiary Xinnowe (300765.SZ) was successfully listed on the GEM, and Shiyao Group achieved a new era of the "red chip + A" financing pattern. Currently, there are more than 10 pharmaceutical production bases in Hebei, Shanxi, Shandong, Jiangsu, Jiangxi, Tianjin and other provinces and cities. The product sales are spread to more than 100 countries and regions around the world, and 36 varieties have sales of more than 100 million yuan.

Jiangsu Hengrui Medicine Co., Ltd.

Founded in 1970, Hengrui Medicine is an international pharmaceutical company engaged in the development and promotion of innovative and high-quality drugs. It focuses on the research and development of new drugs in the fields of anti-tumor, surgical drugs, autoimmune diseases, metabolic diseases, cardiovascular diseases and other fields. For many years, Hengrui Medicine has always been rooted in China and facing the world, focusing on health, focusing on cutting-edge fields, and overcoming difficulties to promote high-quality development of the pharmaceutical industry. The company regards scientific and technological innovation as its first development strategy and continues to invest in R&D with high intensity. The company has invested a total of 23.8 billion yuan in R&D in the past decade, of which 6.203 billion yuan of R&D investment in 2021, and the proportion of R&D investment in operating income reached 23.95%, ranking The forefront of the industry. The company has successively established R&D centers or branches in Lianyungang, Shanghai, Chengdu, the United States and Europe, and has built a global R&D team with a scale, professional and comprehensive capabilities of more than 5,000 people. At present, the company has 12 innovative drugs including reverutamide, hitrapopal, carrilizumab, etc., and the first new drug introduced by the company has also been approved for marketing. This is also the company's external cooperation. Among the products, more than 60 innovative drugs are being clinically developed, and more than 260 clinical trials are being carried out at home and abroad. The company has rich R&D pipelines. In addition to the traditional advantageous tumor field, it also prospectively and widely deploys multiple therapeutic areas such as autoimmune diseases, pain management, cardiovascular diseases, and metabolic diseases. The company has also established a number of new technology platforms with independent intellectual property rights and internationally advanced to provide strong basic guarantees for innovation and research and development. As of the end of 2022, the company has applied for 2,064 invention patents, 583 PCT patents, 507 valid domestic invention patents, and 618 authorized patents from Europe, America, Japan and other countries. The company continues to steadily promote internationalization. As of the end of 2021, Hengrui Pharmaceutical products have entered more than 40 countries, and are continuing to accelerate the development of global markets and focus on emerging markets. The company insists on both independent research and development and open cooperation, and strengthens international cooperation on the basis of endogenous development. Through cooperation with American and Korean companies, the company authorizes innovative drugs with independent intellectual property rights such as SHR2554, carrilizumab, SHR0302 to the public. In addition, Hengrui Medicine has obtained more than 20 registration approvals including injections, oral preparations and inhaled anesthetics in Europe, the United States and Japan, improving the accessibility of drugs in patients in different regions around the world. Perseverance leads to a long-term future, and a prosperous life. In the future development, Hengrui will continue to adhere to the mission of "technology-based, creating a healthy life for mankind", with the vision of "focusing on innovation and building a multinational pharmaceutical group", accelerate technological innovation, and strive to develop more new drugs, Good medicines benefit patients and better serve healthy life!

Yangzhou Sanyao Pharmaceutical Co., Ltd.

Yangzhou Sanyao Pharmaceutical Co., Ltd. is located in Yangzhou City. It has now become a modern national high-tech enterprise integrating pharmaceutical research and development, pharmaceutical production and marketing. The company covers an area of ​​190,000 square meters, a building area of ​​85,000 square meters, and a greening area of ​​61%. It produces ten dosage forms such as suspensions, tablets, capsules, granules, mixtures, oral solutions, syrups, and raw materials. There are more than 70 varieties in total, and it is a modern production base designed and built in accordance with the requirements of GMP and has a large number of products. The company introduced production and quality testing equipment with advanced domestic level and a scientific and rigorous production and quality control system, which has brought the company's production scale and product quality to a new level, and has fully demonstrated the vitality of Yangzhou Sanyao. The research and development of Yangzhou Sand Pharmaceuticals is market-oriented, with the goal of serving the society and creating health, focusing on innovative drugs with broad market potential. The company has formed a strong R&D team to independently develop with its own technology. The research and development of new products has provided strong impetus for the company's sustainable and stable development. At present, the company has a strong product portfolio of more than 70 drugs, focusing on the treatment areas of cardiovascular, anti-infection, gastrointestinal tract, respiratory tract, neurological and other diseases. Including the first-class national drug and the new generation of fluoroquinolone anti-infective drug Gatifloxacin mesylate capsule (Tianxin). The main products include Tianqian (ibuprofen suspension), Shuangchang (ambroxol hydrochloride) tablets and oral solutions, Rifaximin dry suspension (Qianerfen), Tramadol hydrochloride granules, metformin hydrochloride Glibenbutyric tablets, clarithromycin capsules, Junyi (Trazosin hydrochloride capsules), simvastatin capsules, etc. The raw materials include ambroxol hydrochloride, alanylglutamine, methonamide hydrochloride, ornizole, saxagliptin, etc.

Kangzhi Pharmaceutical Co., Ltd.

Kangzhi Pharmaceutical Co., Ltd. is a listed company focusing on children's health (stock abbreviation: Kangzhi Pharmaceutical, stock code: 300086). The main business covers children's medicine, maternal and infant health products, medical services and other fields. It is a national high-tech enterprise and has established a postdoctoral research station with children's medicine as its main research direction. The company adheres to the corporate purpose of "being sincere and good at doing medicine and benefiting mankind", actively implements the "children's big health strategy" and "quality strategy", and ingeniously creates a national brand of the children's big health industry. Kangzhi Pharmaceutical has been deeply engaged in the children's drug market for many years and has formed a complete product line. It is one of the few pharmaceutical companies in China that have the entire industrial chain of children's drug research and development, production and sales. The company's territory is nationwide, with five major production bases in Hainan, Beijing, Hebei, Liaoning and Guangdong provinces and cities, and highly automated and intelligent production lines. The company has advanced R&D equipment and excellent R&D team. In 2018, Kangzhi Pharmaceutical acquired Zhongshan Aihu Daily necessities Co., Ltd., and its business layout extended to the maternal and infant health sector. Kangzhi Children's Big Health Map is becoming more and more perfect. Aihu Company has successively established cooperation with many domestic and foreign scientific research institutions and universities, and has been invited to participate in the formulation of the "Liquid Detergent for Infant and Children's Clothing Materials" standards. It is a benchmark enterprise in the field of maternal and infant health in China. At the beginning of 2020, the new crown pneumonia epidemic swept the world. Kangzhi Pharmaceutical was ordered to volunteer to produce masks and other protective materials in an emergency. It built Hainan's first disposable medical mask production line in just 8 days, and successfully obtained ENISO13485:2016 EU Quality Management System Certification , and in September 2020, he became a manufacturer of anti-epidemic mask materials for the United Nations Development Program.